Key Takeaways

  • SightGlass Vision’s DOT spectacle lenses reduced myopia progression by more than 1D on average after 2 years in Chinese children aged 6 to 10
  • In the full study population, DOT lenses slowed myopia progression by 67% and axial length growth by 62% compared with single vision lenses
  • Additional ARVO 2026 research showed consistent visual performance and no significant link between pupil size and treatment effectiveness in children wearing DOT lenses

SightGlass Vision announced new 2-year clinical data demonstrating that its DOT spectacle lenses for myopia control significantly reduced myopia progression in Chinese children, reinforcing the company’s contrast management technology as a high-efficacy, non-defocus treatment option.

The findings, presented at the ARVO 2026 Annual Meeting, showed that children aged 6 to 10 experienced more than 1 diopter (D) less myopia progression on average after 2 years of wearing DOT lenses compared with children wearing conventional single vision lenses. The results build on previously reported 12-month data from the company’s CATHAY clinical trial.

Across the broader study population of Chinese children aged 6 to 13, DOT lenses slowed average myopia progression by 0.78D and reduced axial length progression by 0.40 mm over 2 years compared with the control group. According to the company, these findings represent a 67% reduction in myopia progression and a 62% reduction in axial elongation.

The data were presented by Jennifer Hill in a presentation titled, “Control of Myopia Using Contrast Modulation Spectacle Lenses in a Chinese Population: 24-Month Results.”

“Our CATHAY 2-year results add to the robust data that establishes DOT lenses as a high-efficacy, non-defocus spectacle solution crucial for practices engaged in myopia management to complete their portfolio,” said Andrew Sedgwick, CEO of SightGlass Vision. “The strength of the outcomes, particularly in younger children, reinforces the importance of early intervention.”

Unlike traditional defocus-based myopia control solutions, DOT lenses are designed to reduce retinal contrast signaling through embedded light scattering elements. SightGlass Vision says the latest CATHAY findings further validate the company’s contrast management approach.

Additional study outcomes showed that 59% of children wearing DOT lenses experienced 0.50D or less myopia progression after 2 years, compared with just 19% of children in the control group. The differences were statistically significant, with a P-value of less than 0.0001.

The CATHAY study follows the company’s 4-year CYPRESS trial conducted in North America and was designed to evaluate the safety and efficacy of DOT lenses in Chinese children. The multicenter study enrolled participants across five clinical sites in China, with 172 myopic children aged 6 to 13 completing the second year of the trial.

“The breadth of clinical research now available demonstrates why practitioners should adopt DOT lenses as a treatment strategy for myopia control,” said David Webley, senior director of clinical, medical, and professional affairs at SightGlass Vision. “The strong efficacy results from the CATHAY study continue to validate that contrast management, with DOT lenses, is an effective tool in the fight against the myopia epidemic.”

Additional research presented at ARVO 2026 explored DOT lens performance and wearer experience. One study, “Pupil Size Effect on Myopia Progression with Contrast Modulation Spectacle Lenses,” found no significant relationship between pupil size and myopia progression rates among children wearing DOT lenses after 12 months.

A second presentation, “Viewing Behavior with Contrast Modulation Spectacle Lenses,” reported that children demonstrated similar viewing behavior while wearing DOT lenses and standard single vision lenses during a variety of daily activities, suggesting strong visual performance across the lens design.

SightGlass Vision said DOT lenses have now launched commercially in China, Canada, Israel, Spain, and the United Kingdom. Founded in 2016, the company operates as a joint venture between CooperVision and Essilor International.